(S) Etifoxine Development Fund, LLC
SEDF funding the FDA approval process for a uniquely low risk, non-opiate, non-addictive, non-sedating, pain drug without GI side effects.
SEDF was formed by a group of pharmaceutical industry veterans to develop (S)Etifoxine, an active component of an existing, clinically proven safe and effective drug as a novel, first-in-class pain treatment. Our management team and Strategic Advisory Board have extensive experience developing drugs with numerous large and medium sized pharmaceutical companies. (S)Etifoxine should make a significant difference in the way we treat pain.